FdaApplication
BLA 205692
Identifiers
- fda_app_no: BLA205692
Properties
| Property | Value |
|---|---|
| applicant_name | Eli Lilly and Company |
| application_type | BLA |
| approval_date | 2015-12-16 |
Revenue by product
BASAGLAR
| Period | Revenue |
|---|---|
| Q4 2024 | $853.8M |
| Q3 2024 | $161.6M |
| Q2 2024 | $180.8M |
| Q1 2024 | $157.6M |
| Q4 2023 | $913.5M |
| Q3 2023 | $179.6M |
| Q2 2023 | $154.2M |
| Q1 2023 | $209.3M |
| Q4 2022 | $962.1M |
| Q3 2022 | $193.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
BASAGLAR
| Period | Revenue |
|---|---|
| Q4 2024 | $853.8M |
| Q3 2024 | $161.6M |
| Q2 2024 | $180.8M |
| Q1 2024 | $157.6M |
| Q4 2023 | $913.5M |
| Q3 2023 | $179.6M |
| Q2 2023 | $154.2M |
| Q1 2023 | $209.3M |
| Q4 2022 | $962.1M |
| Q3 2022 | $193.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BASAGLAR | INSULIN GLARGINE | 300UNITS/3ML (100UNITS/ML) | Injection |
| BASAGLAR | — | 300UNITS/3ML (100UNITS/ML) | Injection |
2 products